Skip to main content
Infant Bacterial Therapeutics logo

Infant Bacterial Therapeutics — Investor Relations & Filings

Ticker · IBT ISIN · SE0008015259 LEI · 2138008KVBXCRJGP6Z26 ST Manufacturing
Open in API
Filings indexed 212 across all filing types
Latest filing 2020-05-18 AGM Information
Country SE Sweden
Listing ST IBT

About Infant Bacterial Therapeutics

https://ibtherapeutics.com/

Infant Bacterial Therapeutics (IBT) is a pharmaceutical company that develops drugs influencing the human infant microbiome to prevent or treat rare diseases. The company's primary focus is on premature infants, addressing urgent medical needs such as necrotizing enterocolitis (NEC), a potentially lethal inflammatory bowel disorder. Its lead drug candidate, IBP-9414, is a New Biological Entity (NBE) currently in a Phase 3 clinical study. IBT also aims to develop treatments for diseases caused by antibiotic-resistant bacteria. The company is developing its medicines for approval by regulatory agencies, including the FDA and EMA.

Recent filings

Filing Released Lang Actions
Notice to attend the Annual General Meeting of Infant Bacterial Therapeutics
AGM Information Classification · 99% confidence The document is explicitly titled "Notice to attend the Annual General Meeting of Infant Bacterial Therapeutics" and details the procedures for advance voting, the proposed agenda, and specific resolutions to be voted upon, such as the election of the Chairman, Board members, Auditor fees, and remuneration principles. The presence of a detailed agenda for a meeting scheduled for June 16, 2020, and the focus on shareholder voting procedures strongly indicates this is a document related to the Annual General Meeting (AGM). While it contains elements that might appear in other reports (like references to the annual report in the agenda), the primary purpose and structure align perfectly with the materials distributed for an AGM. Therefore, the classification is AGM-R.
2020-05-18 English
Interim / Quarterly Report 2020
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Delårsrapport 1 januari – 31 mars 2020' (Interim Report for Jan 1 – Mar 31, 2020) for Infant Bacterial Therapeutics AB. It contains a CEO commentary, a summary of financial data (income statement/balance sheet items), and significant events during and after the reporting period. It is a comprehensive quarterly financial report, not merely an announcement of a report, as it provides substantive financial data and analysis. Q1 2020
2020-05-11 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Management Statement, January 1-March 31, 2020' and contains substantive financial data, including a table of 'Selected financial data' for the period, as well as management commentary on business operations and significant events. It is a comprehensive report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q1 2020
2020-05-11 English
Major Shareholding Notification 2020
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding for 'Swedbank Robur Fonder AB' in 'Infant Bacterial Therapeutics AB'. It explicitly lists the 'Before the transaction' and 'After the transaction' share quantities and voting rights percentages, noting the 'Reason for major shareholding notification Sell'. This structure is characteristic of a notification regarding a change in significant share ownership, which aligns directly with the definition for Major Shareholding Notification (MRQ). The document is short and contains specific transactional data rather than a full report or an announcement of a report.
2020-04-17 English
Infant Bacterial Therapeutics AB senarelägger årsstämman
AGM Information Classification · 95% confidence The document is a press release dated April 3, 2020, announcing that Infant Bacterial Therapeutics AB is postponing its Annual General Meeting (Årsstämman) from May 11, 2020, to June 16, 2020, due to the coronavirus epidemic. This announcement specifically concerns the scheduling and postponement of the AGM. While it relates to the AGM, it is an announcement about the meeting logistics, not the meeting materials themselves (AGM-R) or the proxy solicitation (PSI). Since it is a specific announcement regarding a shareholder meeting date change, and there isn't a dedicated code for 'AGM postponement notice,' it falls best under the general category for regulatory announcements or shareholder-related news. However, given the focus on the AGM, and the lack of a specific 'AGM Announcement' code, we must check the closest fit. AGM-R is for presentations/materials. Since this is a direct announcement about the AGM schedule, and it is a formal press release, it is most closely related to shareholder meeting information. Given the options, and recognizing this is a formal announcement about the AGM logistics, it is not a standard regulatory filing (RNS) or a proxy statement (PSI). Since the core subject is the Annual General Meeting, and the document is short and announces a change related to it, it is best classified as a general announcement related to shareholder meetings, which often falls under RNS if no better fit exists. However, if we strictly interpret the definitions, it is an announcement about the AGM. Since the document is short and is a press release announcing a change related to the AGM, it is not the AGM materials (AGM-R). It is an announcement. Given the options, RNS (Regulatory Filings/General Announcement) is the safest fallback for a press release announcing a procedural change, although it is highly specific to the AGM. Let's re-evaluate: It is an announcement about the AGM date. If the AGM materials were attached, it would be AGM-R. Since it's just the postponement notice, RNS is the most appropriate general regulatory announcement category for this type of corporate action update that doesn't fit elsewhere.
2020-04-03 Swedish
Infant Bacterial Therapeutics AB postpones Annual General Meeting
AGM Information Classification · 98% confidence The document is a press release dated April 3, 2020, announcing the postponement of the Annual General Meeting (AGM) from May 11, 2020, to June 16, 2020, due to the Corona Epidemic. Although it mentions the AGM, the core content is an announcement about a change in the meeting schedule, not the meeting materials themselves (AGM-R) or the proxy information (PSI). Since it is an announcement related to a general meeting schedule change, and there isn't a specific code for 'AGM postponement announcement', it is best classified as a general Regulatory Filing (RNS) or potentially related to Governance/Board actions, but RNS is the most appropriate fallback for general corporate announcements that don't fit the specific categories like ER, DIV, or DIRS. Given the context of corporate governance events, RNS is the safest general classification for this type of announcement.
2020-04-03 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.